To investigate the clinical effects of RPS24 on patients with hepatocellular carcinoma, we classified the HCC patients into a “high group” (n = 45) and “low group” (n = 41) based on the IHC staining indicators of RPS24 expression. The gene discussed is RPS24; the disease is hepatocellular carcinoma.